Science that’s changing the way medicine is practiced.
Should this be text here about Moleculera Biosciences - and the focus of the company. Precision medicine; AI? or more focused on the panel?
Products in Development for Infection-Triggered Immune-Mediated Disorders: Post COVID Autoimmune Syndrome; Cardiac Panel??
SEE BELOW - i like this - starting with overview of company with lead in to the brain panel.
Helping uncover the root cause for difficult to treat neuropsychiatric illnesses
The Autoimmune Brain Panel™ includes a series of high-complexity blood tests that assists clinicians in determining whether a patient’s neuropsychiatric symptoms may be due to a treatable autoimmune dysfunction, rather than a primary neurologic or psychiatric illness.
Only test of its kind
Providing hope for patients with treatment-resistant conditions.
Approximately 800 million individuals worldwide 1 suffer from neurologic, psychiatric and behavioral disorders. Typically, the standard of care is treatment with psychotropic drugs. However, 20-60% of these patients do not respond to treatment 2 and fail to improve because, in some cases, the root cause is immune-mediated and goes undiagnosed.
That’s all changing with the Autoimmune Brain Panel™ – the only commercially available test of its kind that assists clinicians in diagnosing and treating immune-mediated neuropsychiatric disorders. More than 2,500 clinicians globally are utilizing the Panel to improve the lives of chronically ill patients – giving hope to those most difficult to treat.
Neuropsychiatric symptoms that may be caused by an autoimmune reaction
Maybe stats here
Medical Resources For Healthcare Providers
We are committed to helping healthcare providers improve clinical outcomes for patients with treatment resistant neuropsychiatric symptoms.
Could your symptoms be due to an immune dysfunction?
Answer a few questions to find out if you might benefit from testing with the Autoimmune Brain Panel™.
Learn how clinicians and patients are benefiting from The Autoimmune Brain Panel™
As Featured In
Explore our recent announcements and upcoming events.
Digging Deeper for Answers
The Cunningham Panel™ (Autoimmune Encephalopathy and Basal Ganglia Encephalitis Panel) includes a series of high-complexity blood tests that assists clinicians in determining whether a patient’s neurologic and/or psychiatric symptoms may be due to an underlying autoimmune response.
The Panel measures the levels of autoantibodies directed against specific targets in the brain (Dopamine D1 and D2 receptors, Lysoganglioside GM1 and Tubulin) associated with certain neuropsychiatric symptoms, including involuntary movements and seizures. The fifth test measures the ability of the patient’s autoantibodies to stimulate the CaMKII enzyme that is responsible for the upregulation of brain neurotransmitters, such as dopamine, epinephrine and norepinephrine.
Elevated levels indicate that symptoms may be due to an underlying autoimmune etiology.
What is Autoimmune Epilepsy?
Autoimmune Epilepsy (AE) is a neurologic condition featuring recurrent seizures resulting from an autoimmune process, specifically neural antibodies targeting intracellular, synaptic receptor, or neural cell surface proteins. 1
AE occurs when the immune system produces antibodies that mistakenly target nerve cells in the brain, resulting in involuntary movements and seizures.
Giving You Insights to Improve Patient Care
Identifying autoimmune-induced seizures can change the course of treatment and improve outcomes.
The Cunningham Panel™ test results can support a physician’s clinical diagnosis of autoimmune-associated seizures with laboratory evidence of an underlying immune dysfunction and assist in determining an appropriate treatment regimen, such as immunomodulatory therapy.
